Jason Rhodes Sells 426,412 Shares of Dyne Therapeutics (NASDAQ:DYN) Stock

Dyne Therapeutics, Inc. (NASDAQ:DYN) Director Jason Rhodes sold 426,412 shares of the business’s stock in a transaction that occurred on Thursday, August 13th. The shares were sold at an average price of $26.20, for a total value of $11,171,994.40. Following the transaction, the director directly owned 751,411 shares in the company, valued at $19,686,968.20. This trade represents a 36.20% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Dyne Therapeutics Trading Up 1.8%

NASDAQ:DYN traded up $0.45 during trading hours on Monday, hitting $26.15. The company had a trading volume of 1,317,571 shares, compared to its average volume of 2,103,342. The company has a debt-to-equity ratio of 0.28, a current ratio of 12.02 and a quick ratio of 12.02. The stock has a 50-day moving average price of $22.83 and a 200 day moving average price of $19.50. The company has a market capitalization of $4.88 billion, a PE ratio of -7.85 and a beta of 1.07. Dyne Therapeutics, Inc. has a 52 week low of $11.65 and a 52 week high of $27.31.

Dyne Therapeutics (NASDAQ:DYN) last issued its quarterly earnings data on Thursday, July 30th. The company reported ($1.08) EPS for the quarter, missing the consensus estimate of ($0.75) by ($0.33). On average, equities research analysts predict that Dyne Therapeutics, Inc. will post -3.37 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several analysts have commented on DYN shares. Cantor Fitzgerald initiated coverage on shares of Dyne Therapeutics in a report on Thursday, July 23rd. They issued an “overweight” rating for the company. Evercore set a $33.00 target price on Dyne Therapeutics in a research report on Friday, May 15th. Wall Street Zen cut Dyne Therapeutics from a “sell” rating to a “strong sell” rating in a research note on Saturday, August 1st. Sanford C. Bernstein lifted their price target on Dyne Therapeutics from $23.00 to $24.00 and gave the company a “market perform” rating in a research report on Wednesday, May 13th. Finally, TD Cowen began coverage on Dyne Therapeutics in a research note on Friday, June 26th. They issued a “buy” rating on the stock. Two analysts have rated the stock with a Strong Buy rating, ten have given a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $34.42.

Hedge Funds Weigh In On Dyne Therapeutics

A number of hedge funds have recently added to or reduced their stakes in the company. Hilton Head Capital Partners LLC bought a new stake in Dyne Therapeutics during the first quarter valued at approximately $26,000. Strs Ohio purchased a new position in shares of Dyne Therapeutics during the 4th quarter worth $51,000. Allworth Financial LP bought a new stake in shares of Dyne Therapeutics during the 2nd quarter valued at $62,000. Aster Capital Management DIFC Ltd bought a new stake in shares of Dyne Therapeutics during the 4th quarter valued at $84,000. Finally, Steward Partners Investment Advisory LLC increased its stake in shares of Dyne Therapeutics by 102.1% in the 4th quarter. Steward Partners Investment Advisory LLC now owns 4,880 shares of the company’s stock worth $95,000 after purchasing an additional 2,465 shares in the last quarter. 96.68% of the stock is currently owned by hedge funds and other institutional investors.

Dyne Therapeutics Company Profile

Dyne Therapeutics is a clinical-stage biotechnology company specializing in the development of localized gene regulation therapies for serious rare diseases. The company’s proprietary FORCE (Facilitated Orthogonal Receptor‐mediated Cargo Evaluation) platform is designed to enable targeted delivery of oligonucleotide and gene therapy modalities to skeletal and respiratory muscles. Dyne’s lead programs focus on Duchenne muscular dystrophy (DMD), myotonic dystrophy type 1 (DM1) and facioscapulohumeral muscular dystrophy (FSHD), with preclinical and early clinical studies evaluating safety, tolerability and tissue specificity.

Since its founding in 2019 by Flagship Pioneering, Dyne has advanced multiple product candidates using its modular delivery approach, which couples engineered ligands with therapeutic payloads to improve uptake into muscle cells.